Immune Checkpoint Blockade (ICB) Data

Despite the large number of Immune checkpoint inhibitors (ICB) clinical trials with available molecular data published every year, it is still complicated to assess the reproducibility of immune-oncology (IO) predictive and prognostic biomarkers.

Recently, multiple biomarkers have been reported to be associated with immunotherapy response, however tumor complexity and heterogeneity limit the use of research context biomarkers in clinical practice. We have recently performed a meta-analysis of public clinical genomic datasets of patients treated with immunotherapies to assess the predictive value of published biomarkers and mRNA signatures. The collection of datasets contain a broad number of ICB clinical trials, with both molecular and clinical data available.